On March 16, 2023, BioVaxys Technology Corp. closed the transaction. The company has amended the terms of the transaction.

The company has issued 5,360,000 common shares at a price of CAD 0.125 per share for gross proceeds of CAD 670,000. All common shares issued pursuant to the private placement will be subject to a statutory hold period of four months and one day.